-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) PT Raised to $95 at H.C. Wainwright
-
-
-
-
-
-
-
Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) Following Raised Guidance
-
-
-
-
-
-
-
Goldman Sachs Downgrades Halozyme Therapeutics (HALO) to Sell 'as we approach peak revenue'
-
-
-
-
-
-
-
Leerink Partners Upgrades Halozyme Therapeutics (HALO) to Market Perform
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) PT Raised to $85 at H.C. Wainwright
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) added to Russell 1000
-
459,670 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

